Interestingly, both EPCR [18] and PAR1 [19] are over-expressed in lung adenocarcinomas (LUAD), a subtype of non-small cell lung cancer (NSCLC), which are associated with poor prognosis and decreased patients’ survival [18, 19]. Here, F2R is linked to lung adenocarcinoma.